Vericel to Host First-Quarter 2017 Earnings Webcast and Conference Call on May 10, 2017
May 04 2017 - 3:21PM
Vericel Corporation (NASDAQ:VCEL), a leading developer of
autologous expanded cell therapies for the treatment of patients
with serious diseases and conditions, today announced the following
webcast and conference call:
What: |
|
|
|
|
Vericel Corporation
First-Quarter 2017 Earnings Call |
When: |
|
|
|
|
Wednesday, May 10, 2017
at 8:00am (ET) |
Where: |
|
|
|
|
http://investors.vcel.com/events.cfm |
How: |
|
|
|
|
The conference call
will be available live in the Investors section of the Vericel
website at http://investors.vcel.com/events.cfm. Please
access the site at least 15 minutes prior to the scheduled start
time in order to download the required audio software if
necessary. |
|
|
|
|
|
|
To participate in the live call by telephone, please call (877)
312-5881 and reference Vericel Corporation first-quarter 2017
investor conference call. If calling from outside the U.S., please
use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events.cfm until May
10, 2018. A replay of the call will also be available until 11:00
am (ET) on May 14, 2017 by calling (855) 859-2056, or from outside
the U.S. (404) 537-3406. The conference ID is 11385924.
About Vericel CorporationVericel develops,
manufactures, and markets expanded autologous cell therapies for
the treatment of patients with serious diseases and
conditions. The company markets three cell therapy products
in the United States. Vericel is marketing MACI® (autologous
cultured chondrocytes on porcine collagen membrane), an autologous
cellularized scaffold product indicated for the repair of
symptomatic, single or multiple full-thickness cartilage defects of
the knee with or without bone involvement in adults.
Carticel® (autologous cultured chondrocytes) is an autologous
chondrocyte implant for the treatment of cartilage defects in the
knee in patients who have had an inadequate response to a prior
arthroscopic or other surgical repair procedure. Epicel®
(cultured epidermal autografts) is a permanent skin replacement for
the treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area.
Vericel is also developing ixmyelocel-T, an autologous
multicellular therapy intended to treat advanced heart failure due
to ischemic dilated cardiomyopathy (DCM). For more
information, please visit the company's website at
www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of
Vericel Corporation. © 2017 Vericel Corporation. All
rights reserved.
CONTACT:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2023 to Sep 2024